Exhaled nitric oxide in the diagnosis and management of childhood asthma.
The management of asthma in children and adolescents is currently guided by assessment of clinical symptoms, exacerbation risk and spirometric measure of lung function. The use of biomarkers, an objective measure which indicates normal or pathophysiologic processes and/or the response to a treatment intervention, could greatly enhance the efficacy and safety of current algorithms. Measurement of the fraction of expired nitric oxide in exhaled air (FeNO) has been suggested as a readily determined biomarker that can aid in the diagnosis and management of asthma. FeNO has been used to identify steroid responsive patients, adjust the dose of controller medications, most notably inhaled corticosteroids, and predict relapse during medication taper. In spite of early enthusiasm for the utility of this measure, more recent data suggest a more limited role for FeNO. This review will focus on the use of FeNO in the diagnosis and management of asthma in children and adolescents.
Kercsmar
Carolyn
C
University of Cincinnati, Cincinnati, OH 45229, USA. Carolyn.kercsmar@ cchmc.org
D000293:Adolescent; D000465:Algorithms; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D001944:Breath Tests / Q000379:methods; D002648:Child; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D012129:Respiratory Function Tests
D018927:Anti-Asthmatic Agents; D015415:Biomarkers; D009569:Nitric Oxide